乳糜瀉的全球市場:預測(2022年~2028年)
市場調查報告書
商品編碼
1123134

乳糜瀉的全球市場:預測(2022年~2028年)

Global Celiac Disease Market Research and Forecast 2022-2028

出版日期: | 出版商: Orion Market Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

全球乳糜瀉的市場規模在預測期間內預計將以8.5%的年複合成長率擴大。治療乳糜瀉的各種宣傳計劃和政府舉措是推動全球乳糜瀉市場增長的主要因素。

本報告提供全球乳糜瀉市場相關調查,提供市場概要,以及各治療類型,各診斷類型,各終端用戶,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
  • 主要策略分析
  • COVID-19對主要加入企業帶來的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 機會

第5章 市場區隔

  • 全球乳糜瀉市場,各治療類型
    • 維他命和營養補充品(無麩質)
    • 與類固醇免疫抑製藥
    • 治療用疫苗
  • 全球乳糜瀉市場,各診斷類型
    • 血清學的檢驗
    • 遺傳基因檢驗
    • 小腸切片檢查
  • 全球乳糜瀉市場,各終端用戶
    • 醫院及診斷中心
    • 研究機關

第6章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • ADMA Biologics, Inc.
  • Amgen Inc.
  • Bayer AG
  • Bio Rad Laboratories, Inc.
  • BioLineRX Ltd.
  • Boston Scientific Corp.
  • Bristol-Myers Squibb Co.
  • Calypso Biotech SA
  • ChemoCentryx, Inc.
  • Eli Lilly And Co.
  • GlaxoSmithKline plc
  • ImmunogenX, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.,
  • Merck & Co., Inc.,
  • Sanofi S.A
  • Thermo Fisher Scientific Inc.
  • ZEDIRA GmbH
Product Code: OMR2018269

Global Celiac Disease Market Size, Share & Trends Analysis Report by Treatment Type (Vitamins and Dietary (Gluten-Free) Supplements, Steroids and Immunosuppressive Drugs, and Therapeutic Vaccines), By Diagnostic Type (Serologic Test, Genetic Testing, and Small-Bowel Biopsy) By End-User (Hospitals and Diagnostics Centers, and Research Institutes) Forecast, 2021-2027

The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period. Celiac disease is a digestive disorder in which the body has trouble absorbing nutrients such as lipids, calcium, iron, and folate. It is an autoimmune illness induced by eating gluten, which damages the small intestine's inner lining. Several diseases and conditions, including neurological abnormalities, infertility, reduced bone density, and some cancers, can be caused by the disease. People with type 1 diabetes, down syndrome, autoimmune thyroid disease, microscopic colitis, Addison's disease, and rheumatoid arthritis are at risk for this hereditary condition. Besides, the market for celiac disease therapy is predicted to rise significantly in the forecast period, owing to the development of several anti-inflammatory medications and therapeutic vaccinations that will replace or enhance a gluten-free diet.

The organization of various awareness programs and initiatives taken by the government in various nations for the treatment of celiac disease is a major factor that is driving the growth of the global celiac disease market. With such actions, the government may significantly stimulate market growth. Furthermore, numerous funds are available for R&D operations, which is propelling market expansion. For instance, in 2015, in Italy, children and adults with certain symptoms are tested for celiac disease. Diagnosed celiacs are given vouchers worth up to $168 per month to spend on specially made gluten-free meals. Furthermore, restaurants are educated on how to deal with celiac disease by the Italian Celiac Association and the government. Gluten-free meals are even available at hospitals, schools, and other public eating facilities.

Impact of COVID-19 Pandemic on Global Celiac Disease Market

The global celiac disease market is hit by the COVID-19 pandemic in December 2019. The excruciating need to screen and test large numbers of patients for potential SARS-Cov-2 infection is the most common problem for governments in all COVID-19-affected countries. As the new virus's rapid spread continues to affect communities around the globe, celiac disease susceptibility and risk levels have become a source of concern for the celiac community. The limits imposed to combat COVID-19 may have an impact on celiac disease treatment and gluten-free eating, which is now the sole treatment option for celiac disease. Apart from it, major players were focusing on the clinical trials for the celiac disease therapies, due to the pandemic trials was suspended and impacted negatively on the market growth. The market will witness "V" shape recovery in near future owing to the restart of activities in major economies.

Segmental Outlook

The global celiac disease market can be segmented based on treatment type, diagnostic type, and end-user. Based on the treatment type, the market is classified into vitamins and dietary (gluten-free) supplements, steroids, and immunosuppressive drugs, and therapeutic vaccines. Based on the diagnostic type, the market is classified into the serologic test, genetic testing, and small-bowel biopsy. Apart from it, based on the end-user, the market is bifurcated into hospitals & diagnostics centers, and research institutes.

Global Celiac Disease Market Share by Treatment Type, 2020 (%)

Global Celiac Disease Market Share by Treatment Type

Vitamins and Dietary (Gluten-Free) Supplements Segment holds the significant share in the Global Celiac Disease Market

Among the treatment type for the global celiac disease market, the vitamins and dietary (gluten-free) supplements segment held the highest share in 2020 and is also anticipated to grow significantly during the forecast period. For the treatment of celiac disease, no one pharmaceutical treatment or cure has been approved. As the only treatment option for celiac disease, the gluten-free diet segment is expected to grow. Bakery items, baby food, pasta, and ready meals are all gluten-free products. However, the maintaining a gluten-free diet is difficult and accidental gluten cross-contamination is unavoidable, the researchers such as ImmunogenX are focusing on finding alternative treatment and, possibly a cure for the illness. The compounds bl-7010, larazotide acetate, and vedolizumab are among the most promising in the pipeline for celiac disease.

Regional Outlooks

The global celiac disease market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). North America has been predicted to dominate the global celiac disease market, followed by Europe. The growth is mainly attributed due to an increase in demand for advanced treatment, increased health care expenditure, and a high diagnosis rate. For instance, according to the National Health Expenditure Accounts (NHEA), In 2019, US healthcare spending increased by 4.6 % to $3.8 trillion, or $11,582 per person. Health spending accounted for 17.7 % of the nation's Gross Domestic Product.

Global Celiac Disease Market Growth, by Region 2021-2027

Global Celiac Disease Market Growth, by Region

Asia-Pacific is projected to have a considerable growth in the Global Celiac Disease Market

Asia-Pacific is anticipated to exhibit the significant growth in the global celiac disease market. In the region, countries such as China and India are the most promising economies in terms of growth. This is attributable to growing healthcare infrastructure and high government spending, as well as increasing celiac disease patient awareness and a larger patient pool.

Market Players Outlook

The key players of the global celiac disease market include Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Amgen Inc., Siemens AG, and Bayer AG among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2019, Bristol-Myers Squibb Co., has announced the acquisition of Celgene Corporation, a company that works in celiac disease treatment. This acquisition expands the product portfolio for Bristol company.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global celiac disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Celiac DiseaseIndustry
  • Recovery Scenario of Global Celiac DiseaseIndustry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Celiac Disease Market by Treatment Type
    • 5.1.1. Vitamins and Dietary (Gluten-Free) Supplements
    • 5.1.2. Steroids and Immunosuppressive Drugs
    • 5.1.3. Therapeutic Vaccines
  • 5.2. Global Celiac Disease Market by Diagnostic Type
    • 5.2.1. Serologic Test
    • 5.2.2. Genetic Testing
    • 5.2.3. Small-Bowel Biopsy
  • 5.3. Global Celiac Disease Market by End-User
    • 5.3.1. Hospitals and Diagnostics Centers
    • 5.3.2. Research Institutes

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AbbVie Inc.
  • 7.3. ADMA Biologics, Inc.
  • 7.4. Amgen Inc.
  • 7.5. Bayer AG
  • 7.6. Bio Rad Laboratories, Inc.
  • 7.7. BioLineRX Ltd.
  • 7.8. Boston Scientific Corp.
  • 7.9. Bristol-Myers Squibb Co.
  • 7.10. Calypso Biotech SA
  • 7.11. ChemoCentryx, Inc.
  • 7.12. Eli Lilly And Co.
  • 7.13. GlaxoSmithKline plc
  • 7.14. ImmunogenX, Inc.
  • 7.15. Janssen Pharmaceuticals, Inc.
  • 7.16. Johnson & Johnson Services Inc.,
  • 7.17. Merck & Co., Inc.,
  • 7.18. Sanofi S.A
  • 7.19. Thermo Fisher Scientific Inc.
  • 7.20. ZEDIRA GmbH

LIST OF TABLES

  • 1. GLOBAL CELIAC DISEASE MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBA LVITAMINS AND DIETARY SUPPLEMENTS FOR CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL STEROIDS AND IMMUNOSUPPRESSIVE DRUGS FOR CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL THERAPEUTIC VACCINES FOR CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TYPE, 2020-2027 ($ MILLION)
  • 7. GLOBAL SEROLOGIC TEST IN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL GENETIC TESTING IN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL SMALL-BOWEL BIOPSY IN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 11. GLOBAL CELIAC DISEASE IN HOSPITALS AND DIAGNOSTICS CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL CELIAC DISEASE IN RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TYPE, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 18. EUROPEAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 19. EUROPEAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 20. EUROPEAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TYPE, 2020-2027 ($ MILLION)
  • 21. EUROPEAN CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TYPE, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 27. REST OF THE WORLD CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TYPE, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD CELIAC DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CELIAC DISEASE MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CELIAC DISEASE MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CELIAC DISEASE MARKET, 2021-2027 (%)
  • 4. GLOBAL CELIAC DISEASE MARKET SHARE BY TREATMENT TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL CELIAC DISEASE MARKET SHARE BY DIAGNOSTIC TYPE, 2020 VS 2027 (%)
  • 6. GLOBAL CELIAC DISEASE MARKET SHARE BY END-USER, 2020 VS 2027 (%)
  • 7. GLOBAL CELIAC DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL VITAMINS AND DIETARY SUPPLEMENTSFORCELIAC DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 9. GLOBAL STEROIDS AND IMMUNOSUPPRESSIVE DRUGS FOR CELIAC DISEASE MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL THERAPEUTIC VACCINES FOR CELIAC DISEASE MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL SEROLOGIC TEST IN CELIAC DISEASE MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL GENETIC TESTING IN CELIAC DISEASE MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL SMALL-BOWEL BIOPSY IN CELIAC DISEASE MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL CELIAC DISEASE INHOSPITALS AND DIAGNOSTICS CENTERS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL CELIAC DISEASE IN RESEARCH INSTITUTES MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 16. US CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. CANADA CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. UK CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 19. FRANCE CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. GERMANY CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. ITALY CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. SPAIN CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. REST OF EUROPE CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. INDIA CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. CHINA CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. JAPAN CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. SOUTH KOREA CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. REST OF THE ASIA-PACIFIC CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD CELIAC DISEASE MARKET SIZE, 2020-2027 ($ MILLION)